Monthly vaccination of 6 breast/ovarian cancer patients having HER2/neu-overexpressing tumors with HER2/neu-derived HLA-A2-peptide and GM-CSF as adjuvant, for six months was found to induce interferon-gamma (IFN-γ) secreting CD8+ T lymphocytes targeting HER2/neu. Here, IFNG is linked to ovarian carcinoma.